Baseline characteristics for the total patient population and for subgroups formed according to tertiles by ERO scores and by JSN scores
| Tertile of ERO score | Tertile of JSN score | ||||||
|---|---|---|---|---|---|---|---|
| Variable | Total (n=748) | T1 (n=247) | T2 (n=251) | T3 (n=250) | T1 (n=258) | T2 (n=234) | T3 (n=256) |
| Age, years | 49.9±13.3 | 46.7±13.4 | 50.4±12.3 | 52.7±13.4 | 45.8±12.6 | 50.2±12.3 | 53.9±13.6 |
| Duration, years | 3.1±5.4 | 1.7±2.9 | 2.2±3.6 | 5.4±7.6 | 1.4±2.0 | 2.1±3.6 | 5.7±7.7 |
| ERO score, mean±SD | 11.9±18.7 | 0.6±0.7 | 5.6±2.5 | 29.4±23.9 | 3.1±4.8 | 7.6±8.4 | 24.7±26.1 |
| ERO score, range | 0–169.5 | 0–2.3 | 2.5–11.0 | 11.3–169.5 | 0–30.8 | 0–58.8 | 0–169.5 |
| Narrowing score, mean±SD | 8.0±15.0 | 1.8±4.3 | 3.9±6.4 | 18.3±21.4 | 0.1±0.2 | 2.6±1.3 | 20.9±20.1 |
| Narrowing score, range | 0–120.5 | 0–36.5 | 0–61.5 | 0–120.5 | 0–0.5 | 0.6–5.4 | 5.5–120.5 |
| HAQ-DI | 1.3±0.6 | 1.2±0.6 | 1.4±0.6 | 1.3±0.6 | 1.3±0.6 | 1.3±0.6 | 1.3±0.6 |
| SDAI | 37.2±13.7 | 35.5±14.2 | 39.4±13.8 | 36.8±13.0 | 36.3±13.8 | 37.5±13.6 | 38.0±13.8 |
| SJC28 | 10.7±5.5 | 9.9±5.5 | 11.4±5.6 | 11.0±5.2 | 10.0±5.2 | 10.5±5.4 | 11.7±5.7 |
| TJC28 | 12.8±6.3 | 12.5±6.3 | 13.5±6.2 | 12.4±6.4 | 12.8±6.2 | 12.6±6.1 | 13.0±6.7 |
| PGA (cm | 5.4±2.4 | 5.4±2.4 | 5.6±2.5 | 5.2±2.4 | 5.4±2.4 | 5.6±2.5 | 5.2±2.4 |
| EGA, cm | 5.7±1.9 | 5.4±2.2 | 6.1±1.8 | 5.7±1.7 | 5.6±2.1 | 5.8±1.9 | 5.8±1.7 |
| CRP, mg/dl | 2.6±3.1 | 2.3±3.2 | 2.8±3.5 | 2.5±2.5 | 2.5±3.2 | 2.9±3.4 | 2.3±2.5 |
Bold font denotes significant differences for the indicated variables among tertiles formed by JSN or EROs; these differences were all p<0.0001 except for SJC among ERO tertiles (for which it was 0.025)
CRP, C reactive protein; EGA, evaluator global assessment of disease activity; ERO, erosion; HAQ-DI, Health Assessment Questionnaire Disability Index score; JSN, joint space narrowing; PGA, patient global assessment of disease activity; SDAI, Simplified Disease Activity Index; SJC, swollen joint count; TJC, tender joint count.